Literature DB >> 191590

The effects of neomycin upon transmitter release and action.

J M Wright, B Collier.   

Abstract

These experiments were designed to determine the site and mechanism of action of neomycin on cholinergic transmission. These agents depressed the response of rat diaphragm preparations to phrenic nerve stimulation and to injected acetylcholine (ACh); however, equi-effective neuromuscular blocking concentrations of neomycin (6 x 10(-4) M), streptomycin (1.2 x 10(-3) M) or d-tubocurarine (6.5 x 10(-7) M) reduced the muscle response to injected ACh to 54,27 and 15% of control, respectively, suggesting that neomycin and streptomycin have a presynaptic effect. This finding was confirmed by measuring ACh release from the diaphragm during phrenic nerve stimulation; neomycin (6x10(-4) M) and streptomycin (1.2 x 10(-4) M) depressed ACh release to 29 and 41% of control, respectively. In the cat superior cervical ganglion neomycin (2 x 10(-3) M) blocked ganglionic transmission, did not reduce the response of ganglion cells to injected nicotine and depressed ACh release during preganglionic nerve stimulation to 61% of control in normal Ca++ (2.5 mM) medium and to less than 10% of control in low Ca++ (0.5 mM) medium. The increased accululation of 45Ca induced in rat isolated ganglia by preganglionic nerve stimulation was not changed by d-tubocurarine (2 x 10(-4) M), but was abolished by neomycin (2 x10(-3) M). It is concluded that neomycin blocks ACh release by blocking the influx of Ca++ necessary for transmitter release. This conclusion suggested that neomycin should block noradrenaline release, and this was shown using the anococcygeus preparation from the rat.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 191590

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Neuromuscular and cardiovascular depression produced by prolonged exposure to Polymyxin B.

Authors:  A J de Silva; C Lee
Journal:  Can Anaesth Soc J       Date:  1978-07

2.  Transmitter release at mouse motor nerve terminals mediated by temporary accumulation of intracellular barium.

Authors:  D M Quastel; D A Saint
Journal:  J Physiol       Date:  1988-12       Impact factor: 5.182

3.  Failure of neuromuscular blockade reversal after rocuronium in a patient who received oral neomycin.

Authors:  D L Hasfurther; P L Bailey
Journal:  Can J Anaesth       Date:  1996-06       Impact factor: 5.063

4.  4-Aminopyridine antagonizes the inhibitory effect of pentobarbital on acetylcholine release in the heart.

Authors:  W Weide; K Löffelholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-05       Impact factor: 3.000

5.  Acute effects of neomycin on slowly adapting type I and type II cutaneous mechanoreceptors in the anaesthetized cat and rat.

Authors:  K I Baumann; W Hamann; M S Leung
Journal:  J Physiol       Date:  1990-06       Impact factor: 5.182

6.  The pre- and postjunctional components of the neuromuscular effect of antibiotics.

Authors:  E S Vizi; I A Chaudhry; P L Goldiner; Y Ohta; H Nagashima; F F Foldes
Journal:  J Anesth       Date:  1991-01       Impact factor: 2.078

7.  Gentamicin blockade of slow Ca++ channels in atrial myocardium of guinea pigs.

Authors:  H R Adams; L R Durrett
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

8.  Effect of neomycin on post-tetanic twitch tension of the mouse diaphragm preparation.

Authors:  M C Tsai
Journal:  Br J Pharmacol       Date:  1987-04       Impact factor: 8.739

9.  Neurotoxic aminoglycoside antibiotics are potent inhibitors of [125I]-Omega-Conotoxin GVIA binding to guinea-pig cerebral cortex membranes.

Authors:  H G Knaus; J Striessnig; A Koza; H Glossmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

10.  Aminoglycoside antibiotics block voltage-dependent calcium channels in intact vertebrate nerve terminals.

Authors:  T D Parsons; A L Obaid; B M Salzberg
Journal:  J Gen Physiol       Date:  1992-04       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.